Neurocognitive Profile and Associated Factors Among Children Affected by Sickle Cell Disease in Kinshasa, Democratic Republic of Congo: A Cross-Sectional Study
Abstract
Background/Objectives: Understanding the neurocognitive profile of children with sickle cell disease in the Democratic Republic of Congo is essential, as this condition can significantly affect their development. Our study aims to assess these children’s neurocognitive and developmental profiles and identify related factors. Methods: We conducted a descriptive cross-sectional study involving 287 children, aged 0 to 68 months, using the Mullen Scales of Early Learning and the Gensini Gavito Scale. We also screened for maternal depression using the Hopkins Symptoms Checklist-10. Results: More than half of the participants were boys, with an average age of 4 years. Remarkably, 95.8% (score T < x¯ +2 SD) of children scored below average on the Mullen Scales. Significant associations were found between early neurocognitive development and factors like maternal depression, socioeconomic status, maternal education, age of weaning, and responses to the Ten-Questions Questionnaire (p < 0.005). Conclusion, children with sickle cell disease show below-average cognitive development, with maternal depression being a critical factor. Longitudinal studies are vital to understanding the long-term cognitive effects of sickle cell disease, particularly in the Democratic Republic of Congo, where targeted support is urgently needed.
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 287 participants or records.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.